Payment overview · 2025
General Payments
$3,884.48
168 reported records · 30 companies
Healthcare provider profile · identity verified
Michael Correa, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1083765531
Verified facts
What the public records show
CMS Open Payments records show Michael Correa, MD received $3,884.48 in general payments during 2025 across 168 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 299 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 354 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 354 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Isentress by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 333 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 375 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $546.87 | 14.1% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $389.34 | 10.0% | 24 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $281.15 | 7.2% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $276.91 | 7.1% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $265.27 | 6.8% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $207.92 | 5.3% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $183.82 | 4.7% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $171.22 | 4.4% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $169.70 | 4.4% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $153.65 | 4.0% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $136.65 | 3.5% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $134.10 | 3.5% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $131.95 | 3.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $108.82 | 2.8% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $96.87 | 2.5% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $92.97 | 2.4% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $64.94 | 1.7% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $56.72 | 1.5% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $55.54 | 1.4% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.83 | 1.3% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.09 | 1.2% | 2 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $41.02 | 1.1% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $35.09 | 0.9% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $31.79 | 0.8% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $30.47 | 0.8% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $29.73 | 0.8% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $26.59 | 0.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.11 | 0.7% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $23.83 | 0.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.52 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,884.48 | 168 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $406.50 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $281.15 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $276.91 | 11 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $207.92 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $195.54 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $192.17 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $169.70 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $153.65 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $153.65 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $136.65 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $134.10 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $131.95 | 4 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $119.31 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $117.82 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $117.82 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $108.82 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $108.82 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $96.87 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $94.25 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $92.97 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $66.99 | 11 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $64.94 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $61.87 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $56.72 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.92 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $55.54 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $55.50 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $53.40 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $53.40 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $53.40 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.21 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $48.96 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $48.83 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $48.09 | 2 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $41.02 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $41.02 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $41.02 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $39.21 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| MCOT Normalized: mcot |
Device | Philips North America LLC | $31.79 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $30.47 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $30.47 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $29.73 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $26.59 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 375 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 293 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 354 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 299 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 67 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 333 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 179 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
299 | 60 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
293 | 76 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
61 | 40 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
354 | 86 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
179 | 39 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
109 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
354 | 86 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
234 | 41 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
109 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
333 | 70 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
375 | 86 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2261 | 671 |
| Omeprazole | Omeprazole | 1608 | 481 |
| Amlodipine Besylate | Amlodipine Besylate | 1471 | 446 |
| Gabapentin | Gabapentin | 1042 | 299 |
| Metformin Hcl | Metformin Hcl | 969 | 281 |
| Famotidine | Famotidine | 941 | 301 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 887 | 192 |
| Fluticasone Propionate | Fluticasone Propionate | 829 | 219 |
| Levothyroxine Sodium | Levothyroxine Sodium | 786 | 206 |
| Metoprolol Succinate | Metoprolol Succinate | 771 | 210 |
| Diclofenac Sodium | Diclofenac Sodium | 757 | 258 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 679 | 199 |
| Losartan Potassium | Losartan Potassium | 677 | 200 |
| Glipizide Er | Glipizide | 672 | 187 |
| Pantoprazole Sodium | Pantoprazole Sodium | 598 | 170 |
| Furosemide | Furosemide | 584 | 203 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 580 | 179 |
| Meloxicam | Meloxicam | 558 | 262 |
| Meclizine Hcl | Meclizine Hcl | 544 | 194 |
| Tamsulosin Hcl | Tamsulosin Hcl | 533 | 157 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 525 | 352 |
| Lisinopril | Lisinopril | 484 | 133 |
| Zolpidem Tartrate | Zolpidem Tartrate | 472 | 92 |
| Baclofen | Baclofen | 469 | 206 |
| Prednisone | Prednisone | 424 | 266 |
| Montelukast Sodium | Montelukast Sodium | 416 | 107 |
| Donepezil Hcl | Donepezil Hcl | 404 | 113 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 403 | 88 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 376 | 111 |
| Eliquis | Apixaban | 375 | 86 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 359 | 130 |
| Jardiance | Empagliflozin | 354 | 86 |
| Carvedilol | Carvedilol | 348 | 99 |
| Hydrochlorothiazide | Hydrochlorothiazide | 334 | 103 |
| Ozempic | Semaglutide | 333 | 70 |
| Vascepa | Icosapent Ethyl | 308 | 90 |
| Alendronate Sodium | Alendronate Sodium | 301 | 81 |
| Linzess | Linaclotide | 299 | 60 |
| Farxiga | Dapagliflozin Propanediol | 293 | 76 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 290 | 65 |
| Ibuprofen | Ibuprofen | 280 | 125 |
| Ammonium Lactate | Ammonium Lactate | 262 | 80 |
| Diclofenac Sodium Er | Diclofenac Sodium | 252 | 16 |
| Glipizide | Glipizide | 249 | 74 |
| Clopidogrel | Clopidogrel Bisulfate | 247 | 70 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 239 | 71 |
| Simvastatin | Simvastatin | 237 | 69 |
| Nystatin | Nystatin | 234 | 83 |
| Trulicity | Dulaglutide | 234 | 41 |
| Ezetimibe | Ezetimibe | 229 | 84 |
| Januvia | Sitagliptin Phosphate | 228 | 60 |
| Promethazine Hcl | Promethazine Hcl | 227 | 92 |
| Sertraline Hcl | Sertraline Hcl | 225 | 69 |
| Buspirone Hcl | Buspirone Hcl | 220 | 73 |
| Hydrocortisone | Hydrocortisone | 207 | 85 |
| Clonazepam | Clonazepam | 206 | 46 |
| Atenolol | Atenolol | 202 | 63 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 194 | 76 |
| Fluocinonide | Fluocinonide | 190 | 54 |
| Quetiapine Fumarate | Quetiapine Fumarate | 184 | 51 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 179 | 39 |
| Mirtazapine | Mirtazapine | 176 | 50 |
| Naloxone Hcl | Naloxone Hcl | 174 | 55 |
| Tramadol Hcl | Tramadol Hcl | 174 | 63 |
| Megestrol Acetate | Megestrol Acetate | 167 | 52 |
| Doxepin Hcl | Doxepin Hcl | 159 | 15 |
| Trazodone Hcl | Trazodone Hcl | 154 | 53 |
| Ventolin Hfa | Albuterol Sulfate | 148 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 145 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 43 |
| Memantine Hcl | Memantine Hcl | 135 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 131 | 41 |
| Dicyclomine Hcl | Dicyclomine Hcl | 124 | 47 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 123 | 47 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 120 | 100 |
| Naproxen | Naproxen | 116 | 46 |
| Alprazolam | Alprazolam | 115 | 17 |
| Nifedipine Er | Nifedipine | 114 | 34 |
| Azelastine Hcl | Azelastine Hcl | 112 | 30 |
| Azithromycin | Azithromycin | 112 | 86 |
| Enalapril Maleate | Enalapril Maleate | 112 | 24 |
| Entresto | Sacubitril/Valsartan | 109 | 30 |
| Xarelto | Rivaroxaban | 109 | 27 |
| Tradjenta | Linagliptin | 108 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 38 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 104 | 28 |
| Novolog Flexpen | Insulin Aspart | 103 | 21 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 99 | 23 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 95 | 30 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 93 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 93 | 22 |
| Nabumetone | Nabumetone | 92 | 50 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 92 | 22 |
| Single Use Swab | Alcohol Antiseptic Pads | 91 | 47 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 88 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 28 |
| Metformin Hcl Er | Metformin Hcl | 87 | 31 |
| Diclofenac Potassium | Diclofenac Potassium | 86 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 27 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 80 | 23 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 80 | 20 |
| Valsartan | Valsartan | 80 | 22 |
| Bupropion Xl | Bupropion Hcl | 79 | 20 |
| Terconazole | Terconazole | 76 | 42 |
| Finasteride | Finasteride | 74 | 28 |
| Glimepiride | Glimepiride | 72 | 22 |
| Loperamide | Loperamide Hcl | 72 | 48 |
| Potassium Chloride | Potassium Chloride | 71 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 70 | 21 |
| Pregabalin | Pregabalin | 70 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 19 |
| Procto-Med Hc | Hydrocortisone | 69 | 29 |
| Diazepam | Diazepam | 67 | 16 |
| Mounjaro | Tirzepatide | 67 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 20 |
| Naproxen Sodium | Naproxen Sodium | 65 | 18 |
| Irbesartan | Irbesartan | 64 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 22 |
| Etodolac | Etodolac | 62 | 18 |
| Myrbetriq | Mirabegron | 62 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 43 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 61 | 19 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 61 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 54 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 22 |
| Symbicort | Budesonide/Formoterol Fumarate | 61 | 40 |
| Allopurinol | Allopurinol | 60 | 13 |
| Mometasone Furoate | Mometasone Furoate | 60 | 15 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 60 | 51 |
| Folic Acid | Folic Acid | 59 | 21 |
| Glipizide Xl | Glipizide | 58 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 58 | 19 |
| Torsemide | Torsemide | 58 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 57 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 57 | 19 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 56 | 19 |
| Restasis | Cyclosporine | 55 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 15 |
| Clarithromycin | Clarithromycin | 54 | 34 |
| Proctozone-Hc | Hydrocortisone | 54 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 17 |
| Celecoxib | Celecoxib | 53 | 14 |
| Spironolactone | Spironolactone | 53 | 21 |
| Fluconazole | Fluconazole | 52 | 30 |
| Latanoprost | Latanoprost | 52 | 14 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 52 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 15 |
| Metronidazole | Metronidazole | 50 | 38 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 50 | 24 |
| Ibandronate Sodium | Ibandronate Sodium | 49 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 49 | 13 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 49 | 14 |
| Telmisartan | Telmisartan | 48 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | 20 |
| Valacyclovir | Valacyclovir Hcl | 45 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 11 |
| Methotrexate | Methotrexate Sodium | 44 | suppressed |
| Ranolazine Er | Ranolazine | 44 | 11 |
| Mupirocin | Mupirocin | 41 | 16 |
| Chlorthalidone | Chlorthalidone | 40 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 40 | 17 |
| Ketoconazole | Ketoconazole | 40 | 14 |
| Lumigan | Bimatoprost | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | 17 |
| Rybelsus | Semaglutide | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | 13 |
| Propranolol Hcl | Propranolol Hcl | 37 | 13 |
| Synthroid | Levothyroxine Sodium | 37 | 12 |
| Colchicine | Colchicine | 36 | 15 |
| Halobetasol Propionate | Halobetasol Propionate | 36 | 16 |
| Brilinta | Ticagrelor | 35 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 35 | 25 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 35 | 29 |
| Lactulose | Lactulose | 34 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | 11 |
| Amoxicillin | Amoxicillin | 33 | 21 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 33 | 11 |
| Cilostazol | Cilostazol | 33 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 32 | 18 |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Methimazole | Methimazole | 31 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 31 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 30 | 15 |
| Combigan | Brimonidine Tartrate/Timolol | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Levemir Flexpen | Insulin Detemir | 29 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 27 | 13 |
| Dexilant | Dexlansoprazole | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 25 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 25 | 22 |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 21 |
| Admelog Solostar | Insulin Lispro | 22 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Repaglinide | Repaglinide | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 19 | 11 |
| Lidocaine | Lidocaine | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Isentress | Raltegravir Potassium | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 13 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Easy Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 12 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,884.48 · 168 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, FARXIGA, FUROSCIX, Fluad, Flucelvax, GEMTESA, GLYCATE, GVOKE HYPOPEN, IBSRELA, JARDIANCE, Kerendia, LEQVIO, LINZESS, MCOT, MOUNJARO, NEXLETOL, NURTEC ODT, OFEV, OTEZLA, Omnipod, Ozempic, PREVNAR 20, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VIBERZI, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZENPEP, ZEPBOUND, ZORYVE | 23 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error